Filtered By:
Cancer: Prostate Cancer
Drug: Morphine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Association of Intensive Morphine Treatment and Increased Stroke Incidence in Prostate Cancer Patients: A Population-based Nested Case-Control Study
Conclusions Intense morphine treatment may be associated with an increased stroke incidence in patients with malignancy, and the association is particularly significant for prostate cancer patients.
Source: Japanese Journal of Clinical Oncology - July 26, 2013 Category: Cancer & Oncology Authors: Lee, C. W.-S., Muo, C.-H., Liang, J.-A., Sung, F.-C., Kao, C.-H. Tags: Epidemiology/Public Health, Original Articles Source Type: research

Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: a retrospective population-based time-dependent cohort study
A key element of the palliative care of cancer patients is the management of chronic pain [1]. Opioids continue to be a mainstay in the management of cancer pain in all treatment guidelines [2], and morphine is regarded as the “gold standard” [3–6]. Considered as broad-spectrum analgesics, opioids have multiple side effects and potential complications [7]. Our previous studies indicated that morphine treatment is associated with subdural hemorrhage [8], pulmonary embolism [9], and acute coronary syndrome [10] in cancer patients, as well as increased stroke incidence in prostate cancer patients [11].
Source: Diabetes Research and Clinical Practice - October 12, 2015 Category: Endocrinology Authors: Szu-Pang Yang, Chih-Hsin Muo, I-Kuan Wang, Yen-Jung Chang, Shih-Wei Lai, Cynthia Wei-Sheng Lee, Donald E. Morisky Source Type: research

Connecting Metainflammation and Neuroinflammation Through the PTN-MK-RPTP β/ζ Axis: Relevance in Therapeutic Development
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroi...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research